Research programme: respiratory disorder therapeutics - Signum Biosciences

Drug Profile

Research programme: respiratory disorder therapeutics - Signum Biosciences

Alternative Names: SIG-0980

Latest Information Update: 13 Oct 2010

Price : $50

At a glance

  • Originator Signum Biosciences
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Oct 2010 Preclinical development is ongoing in USA
  • 08 Oct 2008 Preclinical trials in Asthma in USA (Inhalation)
  • 08 Oct 2008 Preclinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top